|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0027651,
umls-concept:C0034538,
umls-concept:C0205195,
umls-concept:C0242184,
umls-concept:C0348080,
umls-concept:C0442805,
umls-concept:C0443252,
umls-concept:C1665688,
umls-concept:C1879688,
umls-concept:C2587213
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-8-21
|
|
pubmed:abstractText |
Mapatumumab, an agonistic tumor necrosis factor-related apoptosis inducing ligand-receptor antibody, exerts highly synergistic apoptotic effects in vitro and in short-term growth delay assays when combined with irradiation. Because it remained unclear in how far these effects influence local tumor control, long-term experiments using a colorectal xenograft model were undertaken.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
198-202
|
|
pubmed:meshHeading |
pubmed-meshheading:19695436-Adenocarcinoma,
pubmed-meshheading:19695436-Animals,
pubmed-meshheading:19695436-Antibodies, Monoclonal,
pubmed-meshheading:19695436-Apoptosis,
pubmed-meshheading:19695436-Cell Hypoxia,
pubmed-meshheading:19695436-Colorectal Neoplasms,
pubmed-meshheading:19695436-Combined Modality Therapy,
pubmed-meshheading:19695436-Dose Fractionation,
pubmed-meshheading:19695436-Dose-Response Relationship, Radiation,
pubmed-meshheading:19695436-Mice,
pubmed-meshheading:19695436-Mice, Nude,
pubmed-meshheading:19695436-Neoplasm Recurrence, Local,
pubmed-meshheading:19695436-Radiation Tolerance,
pubmed-meshheading:19695436-Random Allocation,
pubmed-meshheading:19695436-Regression Analysis,
pubmed-meshheading:19695436-Time Factors,
pubmed-meshheading:19695436-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions.
|
|
pubmed:affiliation |
Department of Radiation Oncology, CCC Tübingen, University of Tübingen, Tübingen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
